Dr Mark Bonyhadi has more than 30 years of experience in biopharmaceutical leadership roles in the US, specifically in developing commercially viable approaches to take cell and gene therapies and regenerative medicine from the lab to the clinic and for subsequent business development.
He was vice president for Research at Juno Therapeutics Inc (acquired by Celgene), director of Global Business Development for Cell Therapy at Invitrogen (acquired by Thermo Fisher) and vice president for Research at Xycte Therapies. Dr. Bonyhadi was formerly the chair of the Industry Liaison Committee for the American Society for Gene and Cell Therapy (2015-2016
